

# OFFICE OF FISCAL ANALYSIS

Legislative Office Building, Room 5200  
Hartford, CT 06106 ◊ (860) 240-0200  
<http://www.cga.ct.gov/ofa>

---

sSB-186

AN ACT CONCERNING COLLABORATIVE DRUG THERAPY  
MANAGEMENT AGREEMENTS AND POLICIES.

---

## ***OFA Fiscal Note***

### ***State Impact:***

<b>Agency Affected</b>	<b>Fund-Effect</b>	<b>FY 23 \$</b>	<b>FY 24 \$</b>
Consumer Protection, Dept.	GF - Cost	98,918	96,668
State Comptroller - Fringe Benefits <sup>1</sup>	GF - Cost	36,646	36,646

Note: GF=General Fund

***Municipal Impact:*** None

### ***Explanation***

The bill allows the creation of collaborative drug therapy management policies and agreements between prescribing practitioners and pharmacists resulting in a cost to the Department of Consumer Protection (DCP) and the Office of the State Comptroller. DCP will have to hire one drug control agent for a total cost<sup>2</sup> of \$135,564 in FY 23 and \$133,314 in FY 24 to review the collaborative drug therapy agreements and enforce the expanded scope of practice for pharmacists.

### ***The Out Years***

The annualized ongoing fiscal impact identified above would continue into the future subject to inflation.

---

<sup>1</sup>The fringe benefit costs for most state employees are budgeted centrally in accounts administered by the Comptroller. The estimated active employee fringe benefit cost associated with most personnel changes is 40.53% of payroll in FY 23.

<sup>2</sup> Total cost includes salary, other expenses, and fringe benefits.